These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines. Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238 [TBL] [Abstract][Full Text] [Related]
5. Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles. Wang J; Zhang Y; Dong S; Zha W; Liu C; Wang Y; Jiang Y; Xing H; Li X Int J Pharm; 2023 Jul; 642():123155. PubMed ID: 37402442 [TBL] [Abstract][Full Text] [Related]
6. Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection. Takanashi A; Pouton CW; Al-Wassiti H Mol Pharm; 2023 Aug; 20(8):3876-3885. PubMed ID: 37491979 [TBL] [Abstract][Full Text] [Related]
7. Novel Ionizable Lipid Nanoparticles for SARS-CoV-2 Omicron mRNA Delivery. Long J; Yu C; Zhang H; Cao Y; Sang Y; Lu H; Zhang Z; Wang X; Wang H; Song G; Yang J; Wang S Adv Healthc Mater; 2023 May; 12(13):e2202590. PubMed ID: 36716702 [TBL] [Abstract][Full Text] [Related]
8. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency. Anderluzzi G; Lou G; Woods S; Schmidt ST; Gallorini S; Brazzoli M; Johnson R; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y J Control Release; 2022 Feb; 342():388-399. PubMed ID: 34896446 [TBL] [Abstract][Full Text] [Related]
9. Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates. Suzuki Y; Miyazaki T; Muto H; Kubara K; Mukai Y; Watari R; Sato S; Kondo K; Tsukumo SI; Yasutomo K; Ito M; Tsukahara K Mol Ther Nucleic Acids; 2022 Dec; 30():226-240. PubMed ID: 36187052 [TBL] [Abstract][Full Text] [Related]
10. Enzyme-Catalyzed One-Step Synthesis of Ionizable Cationic Lipids for Lipid Nanoparticle-Based mRNA COVID-19 Vaccines. Li Z; Zhang XQ; Ho W; Li F; Gao M; Bai X; Xu X ACS Nano; 2022 Nov; 16(11):18936-18950. PubMed ID: 36269150 [TBL] [Abstract][Full Text] [Related]
11. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques. Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002 [TBL] [Abstract][Full Text] [Related]
13. Assessment of adjuvantation strategy of lipid squalene nanoparticles for enhancing the immunogenicity of a SARS-CoV-2 spike subunit protein against COVID-19. Ho HM; Huang CY; Cheng YJ; Shen KY; Tzeng TT; Liu SJ; Chen HW; Huang CH; Huang MH Int J Pharm; 2021 Sep; 607():121024. PubMed ID: 34416331 [TBL] [Abstract][Full Text] [Related]
14. DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study. Toyama K; Eto T; Takazawa K; Shimizu S; Nakayama T; Furihata K; Sogawa Y; Kumazaki M; Jonai N; Matsunaga S; Takeshita F; Yoshihara K; Ishizuka H Vaccine; 2023 Aug; 41(38):5525-5534. PubMed ID: 37586958 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. Song JY; Choi WS; Heo JY; Lee JS; Jung DS; Kim SW; Park KH; Eom JS; Jeong SJ; Lee J; Kwon KT; Choi HJ; Sohn JW; Kim YK; Noh JY; Kim WJ; Roman F; Ceregido MA; Solmi F; Philippot A; Walls AC; Carter L; Veesler D; King NP; Kim H; Ryu JH; Lee SJ; Park YW; Park HK; Cheong HJ EClinicalMedicine; 2022 Sep; 51():101569. PubMed ID: 35879941 [TBL] [Abstract][Full Text] [Related]
16. mRNA Vaccines Against SARS-CoV-2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids. Chen K; Fan N; Huang H; Jiang X; Qin S; Xiao W; Zheng Q; Zhang Y; Duan X; Qin Z; Liu Y; Zeng J; Wei Y; Song X Adv Funct Mater; 2022 Sep; 32(39):2204692. PubMed ID: 35942272 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209 [TBL] [Abstract][Full Text] [Related]
18. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500 [TBL] [Abstract][Full Text] [Related]